Fountain Nathan B 4
4 · Acumen Pharmaceuticals, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Acumen Pharmaceuticals (ABOS) Director Nathan B. Fountain Sells Shares
What Happened Nathan B. Fountain, a director of Acumen Pharmaceuticals, sold 6,400 shares in an open-market transaction on June 9, 2026. The reported weighted-average sale price was $2.23, producing proceeds of approximately $14,273. This was a sale (code S), which is commonly routine liquidity rather than a direct signal of company prospects.
Key Details
- Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely filing).
- Shares sold: 6,400; weighted-average price reported: $2.23; total proceeds ≈ $14,273.
- Price range: sales occurred at prices between $2.2300 and $2.2311 (footnote F1). The reporting person can provide a per-trade breakdown to the SEC, the issuer, or any security holder upon request.
- Shares owned after the transaction: not disclosed in this filing.
- Transaction code: S (Sale). No 10b5-1 plan, tax withholding, gift, or option exercise noted in this filing.
Context Sales by corporate insiders can be for many reasons (liquidity, diversification, etc.); this filing is factual and does not indicate motive. The dollar amount is relatively small for an insider sale, and the filing was submitted the next day, so there is no late-reporting flag on this Form 4.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-06-09$2.23/sh−6,400$14,273→ 48,150 total
Footnotes (1)
- [F1]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.